Randomized, single-blind, placebo-controlled multicenter phase III study to assess the efficacy and safety of expanded autologous adipose-derived stem cells (eASCs) (CX-401), for treatment of complex perianal fistulas in Crohn's disease. FATT 2: Fistula Advanced Therapy Trial (II)
Latest Information Update: 04 Apr 2022
At a glance
- Drugs CX 401 (Primary)
- Indications Crohn's disease; Rectal fistula
- Focus Biomarker; Therapeutic Use
- Acronyms FATT2
- Sponsors Cellerix
- 13 Nov 2012 New trial record